Ogata Fusa, Nagaya Tadanobu, Nakamura Yuko, Sato Kazuhide, Okuyama Shuhei, Maruoka Yasuhiro, Choyke Peter L, Kobayashi Hisataka
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892, United States of America.
Oncotarget. 2017 May 23;8(21):35069-35075. doi: 10.18632/oncotarget.17047.
Near infrared photoimmunotherapy (NIR-PIT) is a newly-developed cancer therapy in which a monoclonal antibody is conjugated to a near-infrared photoabsorber, IR700 to form an antibody photoabsorber conjugate (APC). After the APC binds to cancer cells expressing the cognate antigen, exposure to NIR light results in rapid, highly selective necrotic cell death of the cancer cells with minimal off-target effects. Several hours after NIR-PIT, the tumor vessels become supraphysiologically permeable and circulating APC can therefore readily leak into the already-treated tumor space where it can bind with viable cancer cells that is called super-enhanced permeability and retention effect. The presence of the SUPR effect after NIR-PIT has prompted regimens in which there is a repeat exposure of NIR light 24 hours after the initial NIR-PIT to take advantage of the leakage of additional APC deeper into the tumor. However, this post-treatment APC penetration was fully induced within 3 hours, therefore, it is possible that repeated exposures of NIR light could be administered much earlier than 24 hours and still produce the same effects. To test this idea, we compared several modes of delivering additional doses of light after initial NIR-PIT. We found that repeated exposures of NIR light starting 3 hours after initial NIR-PIT produced equal or superior results to more delayed exposures of NIR light. This finding has practical implications of an easy-to-perform regimen as repeated light exposures could be performed during a single day rather than extending the procedure over two days which is the current recommendation.
近红外光免疫疗法(NIR-PIT)是一种新开发的癌症治疗方法,其中单克隆抗体与近红外光吸收剂IR700偶联,形成抗体光吸收剂偶联物(APC)。APC与表达同源抗原的癌细胞结合后,暴露于近红外光会导致癌细胞迅速、高度选择性地坏死性细胞死亡,且脱靶效应最小。NIR-PIT治疗数小时后,肿瘤血管会出现超生理通透性,循环中的APC因此很容易渗漏到已治疗的肿瘤区域,在那里它可以与存活的癌细胞结合,这被称为超增强渗透滞留效应。NIR-PIT后SUPR效应的存在促使人们采用了这样的治疗方案,即在初次NIR-PIT后24小时重复暴露近红外光,以利用额外的APC更深地渗入肿瘤。然而,这种治疗后APC的渗透在3小时内就完全诱导完成,因此,有可能在比24小时更早的时间重复暴露近红外光,仍然能产生相同的效果。为了验证这一想法,我们比较了初次NIR-PIT后给予额外剂量光的几种方式。我们发现,在初次NIR-PIT后3小时开始重复暴露近红外光,与更延迟暴露近红外光相比,能产生相同或更好的效果。这一发现对于一种易于实施的治疗方案具有实际意义,因为重复光照可以在一天内进行,而不是像目前建议的那样将程序延长至两天。